Published in Bull Cancer on July 01, 2001
Impact of organised programs on colorectal cancer screening. BMC Cancer (2008) 0.80
Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol (2003) 5.78
Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol (1982) 5.49
Immunoglobulins on the surface of human lymphocytes. Lancet (1971) 5.25
Breast cancer (1) N Engl J Med (1992) 4.79
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut (2000) 4.02
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines. Nat New Biol (1972) 3.84
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
ABC of mental health. Mental health emergencies. BMJ (1997) 3.46
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet (2000) 3.26
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ (1997) 3.18
Cancer mortality in workers exposed to phenoxy herbicides, chlorophenols, and dioxins. An expanded and updated international cohort study. Am J Epidemiol (1997) 3.10
Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
A microsatellite linkage map of rainbow trout (Oncorhynchus mykiss) characterized by large sex-specific differences in recombination rates. Genetics (2000) 2.98
Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. Development (1993) 2.95
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Automatic record hash coding and linkage for epidemiological follow-up data confidentiality. Methods Inf Med (1998) 2.80
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet (1997) 2.77
Survival of colorectal cancer patients in Europe during the period 1978-1989. EUROCARE Working Group. Eur J Cancer (1998) 2.74
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer (1982) 2.51
Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. Lancet (1991) 2.50
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer (1981) 2.40
Subpopulations of human peripheral blood lymphocytes distinguished by combined rosette formation and membrane immunofluorescence. Lancet (1972) 2.36
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer (1977) 2.33
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique (2003) 2.25
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25
[Improved prognosis of breast cancer]. Ugeskr Laeger (1994) 2.21
Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med (1985) 2.18
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme. BJOG (2013) 2.16
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol (2012) 2.09
Accident department or general practice? Br Med J (Clin Res Ed) (1986) 2.08
Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy. J Virol (1967) 2.07
The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06
Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol (1986) 2.05
Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells. J Immunol (1983) 2.03
[Occurrence of colorectal cancer among parents of patients with this disease]. Ugeskr Laeger (1991) 2.03
Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer (2003) 1.97
Safety evaluation and risk assessment of the herbicide Roundup and its active ingredient, glyphosate, for humans. Regul Toxicol Pharmacol (2000) 1.97
Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer (1998) 1.96
Thymic origin of atypical lymphoid cells in infectious mononucleosis. Lancet (1973) 1.96
Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer (2008) 1.90
Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique (2008) 1.88
Colorectal adenocarcinoma in patients under 45 years of age: comparison with older patients in a well-defined French population. Dis Colon Rectum (2001) 1.87
Work-related cancer in the Nordic countries. Scand J Work Environ Health (1999) 1.84
European directive on confidential data: a threat to epidemiology. BMJ (1994) 1.84
Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer (2001) 1.76
An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods (1994) 1.76
Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer (1978) 1.75
Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer (1976) 1.75
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol (2006) 1.74
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Tobacco, alcohol, and colorectal tumors: a multistep process. Am J Epidemiol (1995) 1.65
Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer (1983) 1.65
Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res (1978) 1.65
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Use of history science methods in exposure assessment for occupational health studies. Occup Environ Med (2005) 1.64
Colonoscopic screening in first-degree relatives of patients with 'sporadic' colorectal cancer: a case-control study. The Association Nationale des Gastroentérologues des Hôpitaux and Registre Bourguignon des Cancers Digestifs (INSERM CRI 9505) Gastroenterology (1998) 1.62
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol (2004) 1.62
Enterobacter cloacae in a haematology/oncology ward--first impressions. J Hosp Infect (1989) 1.61
Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med (1980) 1.61
Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst (1997) 1.60
Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg (2006) 1.59
How to ensure data security of an epidemiological follow-up: quality assessment of an anonymous record linkage procedure. Int J Med Inform (1998) 1.58
Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther (2005) 1.58
Classification and properties of 64 multiplexed microsphere sets. Cytometry (1998) 1.58
The localization of aggregated human -globulin in the spleens of normal mice. Immunology (1973) 1.57
Cancer incidence and cancer mortality in relation to serum cholesterol. J Natl Cancer Inst (1989) 1.57
Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol (1993) 1.55
Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem (1998) 1.54
Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med (1998) 1.53
European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer (1993) 1.52
Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat (1985) 1.51